“…7 This process can be inhibited either by blocking the receptor with an LT receptor antagonist, such as montelukast, or by preventing the formation of cysteinyl-LTs with a 5-lipooxygenase inhibitor, such as zileuton. LT antagonists (LTAs) have proven efficacious in chronic inflammatory conditions of the airways, including allergic rhinitis, asthma, and aspirinexacerbated respiratory disease (AERD), [8][9][10][11] all diseases that often coexist with CRSwNP. Several studies have shown positive effects of LTAs as a primary treatment for CRSwNP.…”